王峯

1.國家級國家自然科學基金面上項目 PDE3A促進食道小細胞癌發生發展的機制和靶向治療研究 2019-2022

2.國家級國家自然科學基金青年基金 活性氧/NFkB信號通路在腦膠質瘤幹細胞分化中的作用及其調控機制 2013-2016

3.省部級教育部博士點專項基金 腦膠質瘤幹細胞活性氧調控NFkB通路對分化的影響及其作用機制 2013-2016

4.省部級廣州市計劃項目 AMPKα調控腫瘤代謝在結直腸癌發生發展中的作用與機制 2016-2019

5.廣東省食道癌研究所科技計劃青年項目 WNT/β-catenin信號通路在食道小細胞癌耐藥和進展中的作用及其分子機制 2015-2017

6.中山大學青年人才培育計劃 Lgr5在食道小細胞癌轉移和耐藥的作用及其機制 2014-2017

7.中山大學腫瘤防治中心優才項目 中期結直腸癌患者蛋白分型和AMPK信號通路的作用及其機制 2014-2018

8.中山大學腫瘤防治中心留學啓動基金 Lgr5在食道小細胞癌轉移和耐藥中的作用及其調控機制 2014-2016

9.中山大學腫瘤防治中心臨牀醫學科學家培養計劃 AMPKα1 調控谷胱甘肽代謝導致結直腸癌的發生發展 2017-2021

10.中山大學臨牀醫學研究5010計劃項目 一項比較靜脈大劑量維生素C聯合FOLFOX +/-貝伐珠單抗對比FOLFOX +/-貝伐珠單抗一線治療既往未接受過轉移性疾病治療的轉移性結直腸癌的隨機、開放、多中心Ⅲ期臨牀研究 2018-2023 ^[1] 

2019年度國家科學技術進步獎二等獎/第二完成人(2/10)

2018年度中華醫學科技獎一等獎/第三完成人（3/15）

2018年度教育部科技進步獎一等獎/第四完成人（4/15）

2018年度廣東省科技進步一等獎/第四完成人（4/15）

“珠江科技新星”

全國“35位35歲以下最具潛力青年腫瘤醫生”

“羊城好醫生”

第四屆廣州國際腫瘤學會議 會議投稿一等獎

中山大學腫瘤防治中心優秀青年人才 ^[1] 

2023年5月12日，被授予第二十五屆廣東青年五四獎章。 ^[3] 

中國抗癌協會腫瘤靶向治療專業委員會第一屆青年委員會副主任委員

中國抗癌協會大腸癌專業委員會委員

中國臨牀腫瘤學會臨牀研究專家委員會委員

廣東省抗癌協會化療專業委員會第五屆委員會委員

廣東省抗癌協會大腸癌專業委員會第四屆委員會常務委員

中國抗癌協會青年理事會理事

中國臨牀腫瘤學會智慧醫療專家委員會委員

廣東省抗癌協會靶向與個體化治療專業委員會第一屆青年委員會主任委員

廣東省抗癌協會腫瘤轉移專業委員會第二屆委員會常務委員

中國臨牀腫瘤學會（CSCO）理事

廣東省抗癌協會遺傳性腫瘤專業委員會第一屆委員會常務委員

中國臨牀腫瘤學會胃癌專家委員會委員

美國臨牀腫瘤學會（ASCO）委員會會員

美國癌症研究協會（AACR）會員 ^[1] 

消化系統腫瘤的內科治療和研究 ^[1] 

週二、週四上午 ^[1] 

1.Wang F*, Zhao Q*, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncology.jamaoncol.2019.2963. (IF:22.4)

2.Wang F*#, Liu DB*, Zhao Q*, Chen G*, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX, Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Research. 2018 May 4. doi: 10.1038/s41422-018-0039-1. (IF:17.8)

3.Wang F*, Wei XL*, Wang FH*, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Annals of Oncology. 2019 Jun 24. pii: mdz197. (IF:14.2)

4.Wu HX*, Chen YX*, Wang ZX*, Zhao Q, He MM, Wang YN, Wang F#, Xu RH#. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. Journal for ImmunoTherapy of Cancer. 2019 Oct 17;7(1):264. (co-corresponding author)(IF:8.7)

5.Wu HX*, Wang ZX*, Zhao Q, Wang F#, Xu RH#. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'. Journal for ImmunoTherapy of Cancer. 2019 Aug 6;7(1):206.(co-corresponding author) (IF:8.7)

6.Lu YX*, Ju HQ*, Liu ZX*, Chen DL, Wang Y, Zhao Q, Wu QN, Zeng ZL, Qiu HB, Hu PS, Wang ZQ, Zhang DS, Wang F#, Xu RH#. Me1 regulates nadph homeostasis to promote gastric cancer growth and metastasis.Cancer Research. 2018; 78(8):1972-1985.(co-corresponding author)(IF:8.4)

8.Wang YN*, Lu YX*, Liu J*, Jin Y*, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM4, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH#, Wang F#. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Oncogene. 2019 Sep 17. 10.1038/s41388-019-1004-2.(IF:6.6)

9.Lu YX*, Ju HQ*, Wang F*, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, Chen G, Yun JP, Zeng ZL, Xu RH#. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Letters. 2016 ;380(1):87-97.(co-first author).(IF:6.5)

10.Wang F*, Xu RH#, Han B, Shi YX, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer, 2007;109:1360-1364.(IF:6.1)

11.Yu HE*, Wang F*, Yu F*, Zeng ZL, Wang Y, Lu YX, Jin Y, Wang DS, Qiu MZ, Pu HY, Kang TB, Xie D, Ju HQ, Xu RH#, Luo HY#. Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. Cell Death & Disease. 2019 May 28;10(6):413.(co-first author) (IF:6.0)

12.Chen ZH*, Qi JJ*, Wu QN*, Lu JH*, Liu ZX, Wang Y, Hu PS, Li T, Lin JF, Wu XY, Miao L, Zeng ZL, Xie D, Ju HQ, Xu RH#, Wang F#. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. Journal of Experimental & Clinical Cancer Research. 2019 May 14;38(1):196. (IF:5.6)

14.Wei XL*, Luo HY*, Li CF*, Jin Y, Zeng ZL, Ju HQ, Wu QN, Wang Y, Mao MJ, Liu WL, Jia WH, Zhang HZ, Li YH, Wang F#, Xu RH#. Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers.International Journal of Cancer. 2017;141(1):152-159. (co-corresponding author).(IF:5.0)

15.He MM*, Wang F*, Jin Y*, Yuan SQ, Ren C, Luo HY, Wang ZQ, Qiu MZ, Wang ZX, Zeng ZL, Li YH, Wang FH, Zhang DS, Xu RH#. (2018), Phase II clinical trial of S‐1 plus nanoparticle albumin‐bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Science. 2018 Oct 3. doi: 10.1111/cas.13813(co-first author)(IF:4.8)

17.Chen WW*, Wang F*, Chen S, Wang L, Ren C, Luo HY, Wang FH, Li YH, Zhang DS#, Xu RH#. Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma. Annals Thoracic Surgery. 2014;97(6):1975-81. (co-first author).(IF:3.9)

18.Wang F*, Bai L*, Liu TS*, Yu YY, He MM, Liu KY, Luo HY, Zhang DS, Jin Y, Wang FH, Wang ZQ, Wang DS, Qiu MZ, Ren C, Li YH#, Xu RH#. Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese Journal of Cancer. 2015;34(6):24.(IF:3.6)

19.Li ZZ*, Bai L*, Wang F*, Zhang ZC, Wang F, Zeng ZL, Zeng JB, Zhang DS, Wang FH, Wang ZQ, Li YH, Shao JY, Xu RH#. Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. Medical Oncology. 2016 ;33(7):71.(co-first author).(IF:3.3)

20.Chen ZH*, Qiu MZ*, Wu XY*, Wu QN, Lu JH, Zeng ZL, Wang Y, Wei XL, Wang F#, Xu RH#. Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients. Journal of Cancer. 2018. (co-corresponding author)(IF:3.2)

21.Wang ZX*, Yang LP*, Wu HX*, Yang DD, Ding PR, Xie D, Chen G, Li YH, Wang F#, Xu RH. Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting. Journal of Cancer. 2019 Jan 1;10(2):388-396. (co-corresponding author)(IF:3.2)

22.Wang F*, Wang FH*, Bai L, Xu RH#. Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. OncoTargets and Therapy. 2014;7:501-511.(IF:3.0)

23.He MM*, Zhang DS*, Wang F*, Wang ZX, Yuan SQ, Wang ZQ, Luo HY, Ren C, Qiu MZ, Jin Y, Wang DS, Chen DL, Zeng ZL, Li YH, He YY, Hao YT, Guo P, Wang FH, Zeng YX, Xu RH#. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemotherapy and Pharmacology. 2017.(co-first author) (IF:3.0)

24.Wang F*, Xu RH#, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008; 8:115.(IF:2.9)

25.Han J*, Wang F*, Yuan SQ, Guo Y, Zeng ZL, Li LR, Yang J, Wang DS, Liu MY, Zhao H, Liu KY, Liao JW, Zou QF#, Xu RH#. Reduced expression of p21-activatedprotein kinase 1 correlates with poor histological differentiation in pancreatic cancer. BMC Cancer. 2014;14(1):650. (co-first author).(IF:2.9)

26.Chen WW*, Wang F*, Zhang DS*, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Ren C, Wei XL, Wu WJ, Li YH, Xu RH#. Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases. BMC Cancer. 2014;14:222. (co-first author).(IF:2.9)

27.Wang F*, He MM*, Wang ZX*, Li S, Jin Y, Ren C, Shi SM, Bi BT, Chen SZ, Lv ZD, Hu JJ, Wang ZQ, Wang FH, Wang DS, Li YH, Xu RH#. Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer. 2019 May 16;19(1):460. (IF:2.9)

28.Wang F*, Yuan SQ*, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, Rao HL, Xia Y, Jiang WQ, Huang HQ, Xia ZJ, Sun XF, Xu RH#. High hepatits B virus infection in B-cell lymphoma tissue and its potential clinical relevance. European Journal of Cancer Prevention. 2012; 21(3):261-7.(IF:2.3)

29.Yang LP*, Wang ZX*, He MM*, Wu HX*, Yuan SQ, Wang W, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F#, Xu RH#. A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients. Cancer Management and Research. 2019 May 2;11:3993-4003. (co-corresponding author)(IF:2.2)

30.Wang ZX*, Wu HX*, Xie L*, Wang YN*, Yang LP, He MM, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F#, Xu RH#. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Network Open. 2019 May 3;2(5):e193433. (co-corresponding author)(IF:Not Available) ^[1]